In An Organic Compound Patents (Class 424/1.65)
-
Patent number: 7767194Abstract: Cyanine and indocyanine dye compounds and bioconjugates are disclosed. The present invention includes several cyanine and indocyanine dyes, including bioconjugates of the same, with a variety of bis- and tetrakis (carboxylic acid) homologues. The compounds of the invention may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive agents. The small size of compounds of the invention allows favorable delivery to tumor cells as compared to larger molecular weight imaging agents. Further, use of a biocompatible organic solvent such as dimethylsulfoxide may be said to assist in maintaining the fluorescence of compounds of the invention.Type: GrantFiled: June 6, 2005Date of Patent: August 3, 2010Assignee: Mallinckrodt Inc.Inventors: Samuel I. Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
-
Patent number: 7767796Abstract: The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalized at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimize lipophilicity and steric hulk. Protected versions of the chelators are provided which permit conjugation with a wide range of targeting molecules without interfering reactions with the amine nitrogens of the tetra-amine chelator. Syntheses of the functionalised chelators are described, together with bifunctional chelate precursors. Radiopharmaceutical compositions comprising the technetium metal complexes of the invention are described, together with non-radioactive kits for the preparation of such radiopharmaceuticals.Type: GrantFiled: July 19, 2005Date of Patent: August 3, 2010Assignee: GE Healthcare LimitedInventors: Anthony Eamonn Storey, Harry John Wadsworth, Nigel Anthony Powell, Philip Duncanson
-
Publication number: 20100189644Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, ARGINETIX, INC.Inventors: DAVID W. CHRISTIANSON, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
-
Publication number: 20100189643Abstract: The present invention provides conjugate compounds comprising (a) an active compound; (b) optionally, but in some embodiments preferably, an affinity binding agent; and (c) a block copolymer, the block copolymer comprising: (i) a first elastin-like polypeptide having a first Tt and (U) a second elastin-like polypeptide having a second Tt greater than the first Tt. Method for the targeted delivering of an active compound in vivo to a selected region within a subject with such agents are also described.Type: ApplicationFiled: July 17, 2007Publication date: July 29, 2010Applicant: DUKE UNIVERSITYInventors: Ashutosh Chilkoti, Matthew Robert Dreher, Daniel Eugene Meyer
-
Patent number: 7763234Abstract: A pharmaceutical of the general formula Z—(L)n-V, wherein V denotes an amino acid sequence X1-X2-Val-Tyr-Ile-His-Pro-X8-X9-X10; L denotes a bond or a linker; Z denotes a group that optionally can carry an imaging moiety M; X1 denotes an amino acid; X2 denotes Arg or N-alkylated Arg or a mimetic of Arg; X8, X9 and X10 constitute an ACE cleavage site; Z forms a bond with the amino acid X1 optionally through the linker L; and M where denotes an imageable moiety capable of detection either directly or indirectly in a diagnostic imaging procedure.Type: GrantFiled: March 3, 2005Date of Patent: July 27, 2010Assignee: GE Healthcare ASInventor: Dagfinn Lovhaug
-
Publication number: 20100183509Abstract: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.Type: ApplicationFiled: December 4, 2009Publication date: July 22, 2010Inventors: John W. BABICH, Craig Zimmerman, John Joyal, Kevin P. Maresca, John Marquis, Genliang Lu, Jian-cheng Wang, Shawn Hillier
-
Publication number: 20100183508Abstract: A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4?/or ReO4?, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4?/or ReO4? avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.Type: ApplicationFiled: January 16, 2009Publication date: July 22, 2010Inventors: Tsai-Yueh LUO, I-Chung Tang, Show-Wen Liu, Yu-Lung Wu, Cheng-Hsien Lin, Cheng-Fang Hsu, Kwei-Luen Hsu, Chang-Mau Sheng, Ching-Jun Liou, Te-Sheng Liang
-
Publication number: 20100178247Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.Type: ApplicationFiled: December 4, 2009Publication date: July 15, 2010Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
-
Publication number: 20100178246Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.Type: ApplicationFiled: December 4, 2009Publication date: July 15, 2010Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
-
Patent number: 7754188Abstract: The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.Type: GrantFiled: June 25, 2004Date of Patent: July 13, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: H. Donald Burns, Alex M. Chen, Raymond E. Gibson, Mark T. Goulet, William K. Hagmann, Terence G. Hamill, James P. Jewell, Linus S. Lin, Ping Liu, Andrey V. Peresypkin
-
Patent number: 7754190Abstract: Neurophysiologic information such as quantitative electroencephalography (QEEG) is used in a method for classifying, diagnosing, and treating physiologic brain imbalances. Neurophysiologic information is also used to guide sample selection in clinical tests for psychopharmacologic drug candidates. Finally, neurophysiologic information is used for remotely assessing and treating patients with physiologic brain imbalances.Type: GrantFiled: June 23, 2003Date of Patent: July 13, 2010Assignee: CNS Response, Inc.Inventor: Stephen Suffin
-
Publication number: 20100172834Abstract: Disclosed here is a method for measuring the kinetics (i.e., the molecular flux rates—synthesis and breakdown or removal rates) of a plurality of proteins or organic metabolites inn living systems. The methods may be accomplished in a high-throughput, large-scale automated manner, by using existing mass spectrometric profiling techniques and art well known in the fields of static proteomics and static organeomics, without the need for additional biochemical preparative steps or analytic/instrumental devices.Type: ApplicationFiled: August 3, 2009Publication date: July 8, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Mark K. HELLERSTEIN
-
Publication number: 20100166651Abstract: The present invention provides a radiotherapeutic composition comprising a high specific activity tin-117m source of radiotherapeutic atomic electrons and a delivery vehicle, e.g., a chelator or nanosphere or microsphere effective to contain tin-117m therein. The present invention also provides a targeting moiety linked to the delivery vehicle. Further provided are methods of treating a bone-associated pathophysiological condition or imaging the same using the high specific activity radiotherapeutic compositions.Type: ApplicationFiled: December 19, 2006Publication date: July 1, 2010Inventor: Marlene OLIVER
-
Publication number: 20100166656Abstract: The present invention refers to diagnostically or radiotherapeutically useful compounds which are able to selectively bind to lectins, having formula (I) wherein R, R?, R1, R2 and R3 are as defined in the specification; the process for their preparation and the pharmaceutical compositions thereof.Type: ApplicationFiled: February 20, 2008Publication date: July 1, 2010Applicant: BRACCO IMAGING S.P.A.Inventors: Cristiana Campa, Fulvio Uggeri, Sergio Paoletti, Anna Flamigni
-
Patent number: 7745590Abstract: Degradable macromolecular magnetic resonance imaging contrast agents for use in various diagnostic procedures, and methods for synthesizing, using and degrading these agents, are described. The macromolecule contrast agents disclosed in various aspects of this invention are degradable gadolinium compounds which show prolonged plasma retention, and enhanced permeability and retention in solid tumors, but are still capable of being rapidly cleared from the body.Type: GrantFiled: August 15, 2005Date of Patent: June 29, 2010Assignee: University of Utah Research FoundationInventors: Zheng-Rong Lu, Jindrich Kopecek, Dennis L. Parker
-
Patent number: 7744851Abstract: The present invention is directed to a method for preparing an anhydrous 18F-radiolabeled fluorinating agent by a nucleophilic reaction of a hydrated 18F-radiolabeled fluoride ion source with an unsaturated carrier compound; treating the 18F-radiolabeled carrier compound to produce a non-aqueous mixture of the 18F-radiolabeled carrier compound in a solvent; and reacting the 18F-radiolabeled carrier compound with a nucleophilic composition in a nucleophilic reaction to produce an anhydrous 18F-radiolabeled fluorinating agent. The present invention is also directed to an anhydrous 18F-radiolabeled fluorinating agent comprising the formula [QnM]x+(18F?)x. Additionally, the present invention is directed to an 18F-radiolabeled fluorinated radiopharmaceutical or an 18F-radiolabeled fluorinated radiotracer prepared by reacting the anhydrous 18F-radiolabeled fluorinating agent with a drug intermediate.Type: GrantFiled: July 16, 2007Date of Patent: June 29, 2010Assignee: Board Of Regents Of The University Of NebraskaInventors: Stephen Gregory DiMagno, Haoran Sun
-
Publication number: 20100150831Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.Type: ApplicationFiled: November 4, 2009Publication date: June 17, 2010Applicant: ChemoCentryx, Inc.Inventors: Xi Chen, Pingchen Fan, Mark M. Gleason, Juan C. Jaen, Lianfa Li, Jeffrey P. McMahon, Jay Powers, Yibin Zeng, Penglie Zhang
-
Publication number: 20100150832Abstract: The present invention relates to biodegradable biocompatible polyketals, methods for their preparation, and methods for treating animals by administration of biodegradable biocompatible polyketals. In one aspect, a method for forming the biodegradable biocompatible polyketals comprises combining a glycol-specific oxidizing agent with a polysaccharide to form an aldehyde intermediate, which is combined with a reducing agent to form the biodegradable biocompatible polyketal. The resultant biodegradable biocompatible polyketals can be chemically modified to incorporate additional hydrophilic moieties. A method for treating animals includes the administration of the biodegradable biocompatible polyketal in which biologically active compounds or diagnostic labels can be disposed. The present invention also relates to chiral polyketals, methods for their preparation, and methods for use in chromatographic applications, specifically in chiral separations.Type: ApplicationFiled: November 18, 2009Publication date: June 17, 2010Applicant: The General Hospital CorporationInventor: Mikhail I. Papisov
-
Publication number: 20100150833Abstract: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus.Type: ApplicationFiled: February 17, 2010Publication date: June 17, 2010Inventors: Gilles D. Tamagnan, David Alagille, Herve Da Costa
-
Patent number: 7736625Abstract: Photochemical demethylation reactions in solutions of thiazine dyes, in which the dye molecules act as both sensitizer and substrate, are reduced by quenching triple-state dye molecules, returning them to the unreactive ground state.Type: GrantFiled: December 8, 2008Date of Patent: June 15, 2010Assignee: Zila, Inc.Inventor: Douglas D. Burkett
-
Publication number: 20100143248Abstract: A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.Type: ApplicationFiled: June 23, 2009Publication date: June 10, 2010Applicants: President and Fellows of Harvard College, Organix, Inc., The General Hospital CorporationInventors: Bertha K. Madras, Alan J. Fischman, Peter C. Meltzer
-
Publication number: 20100143249Abstract: The present invention is directed towards novel folate-conjugates of formula I wherein F is a folate or derivative thereof, Z1, Z2, Z3 are independently of each other C or N, S1 to S4 are independently of each other a single bond or a spacer, Ra, Ra?, and Rb are donor groups and/or another group F, Rc is optionally another group F and n is 1 or 2. The invention further contemplates the corresponding metal-chelate complexes as well as pharmaceutical compositions thereof, and their uses in diagnostic imaging and radiotherapy.Type: ApplicationFiled: April 11, 2008Publication date: June 10, 2010Applicant: MERCK EPROVA AGInventors: Rudolf Moser, Roger Schibli, Cristina Magdalena Muller, Viola Groehn, Urs Michel, Christoph Sparr, Thomas Leighton Mindt
-
Publication number: 20100140483Abstract: A method for cardiac imaging is provided, including administering to an adult human subject an amount of a teboroxime species having a radioactivity of less than 5 mCi at a time of administration, and performing a SPECT imaging procedure of a cardiac region of interest (ROI) of the subject. Other embodiments are also described.Type: ApplicationFiled: November 13, 2007Publication date: June 10, 2010Inventors: Benny Rousso, Dalia Dickman, Yael Nir
-
Patent number: 7732558Abstract: A dendritic compound of the following structure: PDn-Z-L is disclosed. In the structure above, P is X—(CH2CH2—O)r—, r is an integer ranging from 1000 to 4000, X is OH, NH2, or OR, R is C1 to C10alkyl, Dn is a residue of branched C3 to C30 polyol compounds, n is the quantity of layers of the residue of branched compounds and is an integer equal to or greater than 1, L is a metal cation, Z is the residue of a C3 to C30 compound with multi functional groups. The functional groups illustrated above can be carboxylic groups, amino groups, amide groups, or chelating groups. The carboxylic groups, ester groups, amino groups, or amide groups bind to Dn, and the chelating groups bind to the metal cations.Type: GrantFiled: December 27, 2005Date of Patent: June 8, 2010Assignee: Industrial Technology Research InstituteInventors: Abraham Josephk, Hui-Ju Cho, Yu-Hau Shih, Chao-Hung Kao, Huang-Chien Liang
-
Patent number: 7731936Abstract: Provided are radiolytically and metabolically stable metal complexes based on tetrathiol ligands useful for nuclear medical diagnostics and in endoradionuclide therapy. Methods for their preparation are also provided. The complexes can have a central ligand, Y, that can be 99mTcO, 186ReO, 188ReO, 99mTcN, 186ReN or 188ReN.Type: GrantFiled: April 28, 2005Date of Patent: June 8, 2010Assignee: Forschungszentrum Rossendorf E,VInventors: Tobias Heinrich, Bernd Johannsen, Hans-Juergen Pietzsch, Sepp Seifert, Hartmut Spies
-
Publication number: 20100135906Abstract: Radiolabeled tracers for sulfotransferases (SULTs), their synthesis, and their use are provided. Included are substituted phenols, naphthols, coumarins, and flavones radiolabeled with 18F, 123I, 124I, 125I, or 11C. Also provided are in vivo techniques for using these and other tracers as analytical and diagnostic tools to study sulfotransferase distribution and activity, in health and disease, and to evaluate therapeutic interventions.Type: ApplicationFiled: March 31, 2008Publication date: June 3, 2010Inventors: Jorge R. Barrio, Vladimir Kepe, Small W. Gary, Nagichettiar Satyamurthy
-
Patent number: 7727511Abstract: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.Type: GrantFiled: December 11, 2006Date of Patent: June 1, 2010Assignee: General Electric CompanyInventors: Tiberiu Mircea Siclovan, Michael Christopher Montalto, Tun Chiao Hubert Lam, Eric Dustin Agdeppa, Amy Casey Williams, Cristina Tan Hehir
-
Patent number: 7718781Abstract: The present invention provides hydroxypyridinone and hydroxypyrimidone chelating agents. Also provides are Gd(III) complexes of these agents, which are useful as contrast enhancing agents for magnetic resonance imaging. The invention also provides methods of preparing the compounds of the invention, as well as methods of using the compounds in magnetic resonance imaging applications.Type: GrantFiled: July 30, 2004Date of Patent: May 18, 2010Assignee: The Regents of the University of CaliforniaInventors: Kenneth N. Raymond, Daniel M. J. Doble, Christopher J. Sunderland, Marlon Thompson
-
Patent number: 7718160Abstract: The invention, in one aspect, relates to radiolabeled compounds. The invention also relates to radiolabeled liposomes and methods of making and using thereof. The invention also relates to kits for preparing radiolabeled liposomes.Type: GrantFiled: May 22, 2003Date of Patent: May 18, 2010Assignee: The Board of Regents of the University of Texas SystemInventors: Ande Bao, William T. Phillips, Beth Goins
-
Patent number: 7713514Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.Type: GrantFiled: August 4, 2006Date of Patent: May 11, 2010Assignee: Mallinckrodt Inc.Inventors: Gary L. Cantrell, B. Daniel Burleigh
-
Publication number: 20100111859Abstract: A method for visualizing biological material, preferably by MRI, comprising the steps of: (i) bringing a population of coated nanoparticles into contact with said biological material, each of which nanoparticles comprises a) a metal oxide of a transition metal, said metal oxide preferably being paramagnetic and preferably comprising a lanthanide (+III) such as gadolinium (+III), and b) a coating covering the surface of the core particle, and (ii) recording the image; wherein the coating is hydrophilic and comprises a silane layer which is located next to the surface of the core particle and comprises one or more different silane groups which each comprises an organic group R and a silane-siloxane linkage where a) R comprises a hydrophilic organic group R? and a hydrophobic spacer B, b) O is oxygen directly binding to a surface metal ion of the metal oxide, and c) C is carbon and is also part of B.Type: ApplicationFiled: January 10, 2008Publication date: May 6, 2010Inventors: Oskar Axelsson, Kajsa Uvdal
-
Publication number: 20100111858Abstract: The present invention provides conjugates useful for the diagnosis and treatment of diseases associated with the over-expression of COX-2. The conjugates comprise a selective COX-2 targeting carrier, a metal coordinating moiety, and a linker chemically linking the metal coordinating moiety to the carrier. The metals coordinated by the metal coordinating moiety are selected from paramagnetic or radioisotopes. The invention also includes kits comprising a conjugate and a radioisotope solution.Type: ApplicationFiled: January 17, 2008Publication date: May 6, 2010Inventors: Carol P. Howard, Dennis A. Moore
-
Patent number: 7709613Abstract: This invention provides methods of using Rhenium radioisotopes to detect and treat tumors that express a Na+/I? symporter. The invention also provides compositions and methods of making compositions comprising Rhenium radioisotopes for detection and treatment of tumors that express a Na+/I? symporter.Type: GrantFiled: November 7, 2003Date of Patent: May 4, 2010Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Ekaterina Dadachova
-
Publication number: 20100104512Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m—X1p1X2p2X3p3X4p4]z? z B+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.Type: ApplicationFiled: October 9, 2007Publication date: April 29, 2010Applicant: Centre National De La Recherche ScientifiqueInventors: Delphine Felder-Flesch, Jerome Steibel, Annabelle Bertin
-
Publication number: 20100098630Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a phenazine or quinoxaline substituent. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides.Type: ApplicationFiled: December 28, 2007Publication date: April 22, 2010Applicant: AMBRX, INC.Inventor: Zhenwei Miao
-
Publication number: 20100098629Abstract: There are described Compounds of formula (I) in which R3 to R8 are independently selected from hydrogen, halogen, trihaloalkyl, alkyl having 1, 2, 3, 4 or 5 carbon atoms, electron donor groups selected from alkoxy having 1, 2, 3, 4 or 5 carbon atoms, trihaloalkoxy, hydroxy or amino, electron acceptor groups selected from cyano, sulphonic, nitro, or amide; R1 is an optionally substituted phenyl, benzyl or cyclohexyl group; R2 is selected from amino, substituted amino or guanidino groups, Z is a saturated or unsaturated C1-5 hydrocarbon chain, and salts thereof. A process for their preparation and compositions containing them are also described. The Compounds are either agonists or antagonists of a specific adenosine receptor or a number of adenosine receptors and have usefulness for the treatment of inflammation, arthritic conditions, rheumatoid arthritis, Osteoarthritis, mental disorders, or for inducing central nerve regeneration.Type: ApplicationFiled: November 9, 2007Publication date: April 22, 2010Applicant: ACURE PHARMA ABInventors: Torbjorn Lundstedt, Elisabeth Seifert, Per Lek, Arne Boman
-
Publication number: 20100098633Abstract: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by overexpression of seprase include complexes that contains a proline moiety and a radionuclide adapted for radioimaging and/or radiotherapy:Type: ApplicationFiled: September 24, 2009Publication date: April 22, 2010Inventors: Craig ZIMMERMAN, John W. Babich, John Joyal, John Marquis, Jian-cheng Wang
-
Publication number: 20100098631Abstract: The present invention relates to novel 2-heteroaryl substituted indole derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted indole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer?s disease therapeutic agents.Type: ApplicationFiled: March 5, 2008Publication date: April 22, 2010Applicant: ASTRAZENECA ABInventors: Erwan Arzel, Britt-Marie Swahn, David Wensbo
-
Patent number: 7700075Abstract: The present invention provides agents and methods for dual modality virtual colonoscopy that gives both anatomical and functional information using hybrid CT/PET scanning. In preferred embodiments, the present invention provides radiolabeled tumor-specific agents and methods for distinguishing benign polyps from malignant tumors. In further embodiments, the present invention provides compositions and methods useful for distinguishing morphological and functional subregions of a selected region of tissue based on relative levels of phospholipid metabolism. Preferred radiolabeled tumor-specific agents are phospholipid ether analogs labeled with a halogen radioisotope. In certain preferred embodiments, the compositions including radiolabeled phospholipid ether analogs have therapeutic actions in addition to functionally identifying malignant tissue.Type: GrantFiled: July 8, 2005Date of Patent: April 20, 2010Assignee: Cellectar, LLCInventors: Jamey P. Weichert, Marc Longino
-
Publication number: 20100092385Abstract: The present invention relates to novel heteroaryl substituted imidazopyridine derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted imidazopyridine derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.Type: ApplicationFiled: January 21, 2008Publication date: April 15, 2010Applicant: ASTRAZENECA ABInventors: Michaela Vallin, Jonas Malmstrom, David Pyring, Can Slivo, David Wensbo
-
Patent number: 7696331Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.Type: GrantFiled: June 19, 2008Date of Patent: April 13, 2010Assignee: Poniard Pharmaceuticals, Inc.Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
-
Publication number: 20100086480Abstract: Methods for significantly lowering the carbon-14 content, particularly of DNA and histones in vertebrates, especially humans, to significantly below normal background levels and thereby reduce chromosomal damage using dietary supplements based on low radiocarbon DNA and histone precursors optionally including selected low radiocarbon amino acids, preferably including those which contribute the largest share of histone carbon atoms. Administration of the supplements during the earliest and/or most active growth stages of life is particularly beneficial. Components of the low radiocarbon supplements can be produced using a photobioreactor, an aqueous reaction medium and low radiocarbon carbon dioxide. The photobioreactor can be integrated into a body of water or can comprise a mobile, floating structure. Low radiocarbon by-products of photosynthesis can be recycled for use in non-photosynthetic fermentation processes to increase the yield of desirable supplement components.Type: ApplicationFiled: November 3, 2009Publication date: April 8, 2010Applicant: RADIOCARB GENETICS, INC.Inventor: Christopher P. Williams
-
Patent number: 7691985Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.Type: GrantFiled: March 6, 2008Date of Patent: April 6, 2010Assignee: Poniard Pharmaceuticals, Inc.Inventor: Alan R. Fritzberg
-
Publication number: 20100074842Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.Type: ApplicationFiled: November 23, 2007Publication date: March 25, 2010Inventors: Isabel Rego Santos, Antonio Manuel Rocha Paulo
-
Patent number: 7682601Abstract: The present invention relates to a chelating agent of the general formula: (I), wherein m is 0 or 1; X is NR4 or S; Y is SR5, NHR5 or P(R5)2; R1 and R3 are the same or different and are selected from H, alkyl or aryl; R2 is H, COOH, NHR6 or (CH2)nCOOR6; R4 is H, alkyl, aryl, (CH2)nCOOR6 or (CH2)nOR6; R5 is H, alkyl, aryl, (CH2)nCOOR6 or (CH2)nOR6, R6 is H, alkyl or aryl; n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and when R1?R3?CH3, R2, R4 and R5 are not all three H. The invention further relates to a method and kit for the preparation of radiolabeled biomolecules while using the chelating agent.Type: GrantFiled: April 15, 2004Date of Patent: March 23, 2010Assignee: Mallinckrodt Inc.Inventors: Isabel Rego Santos, Joao Domingos Galamba Correia, Antonio Manuel Rocha Paulo, Susana Alves, Rute Vitor
-
Patent number: 7682602Abstract: A near-infrared fluorescing contrast medium which exhibits superior imaging capability and is also difficult to accumulate in a living body, is disclosed, comprising a cyanine compound containing water-solubilizing groups and represented by the following formula. The imaging method by use thereof is also disclosed.Type: GrantFiled: December 14, 2004Date of Patent: March 23, 2010Assignee: Konica Minolta Medical & Graphic, Inc.Inventors: Nobuaki Kagawa, Takeshi Habu, Eiichi Ueda, Akihisa Nakajima
-
Publication number: 20100068138Abstract: A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH?CH—, —C?C—, or cyclohexyl. B is cis or trans —CH?CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2.Type: ApplicationFiled: September 14, 2009Publication date: March 18, 2010Inventors: Amy Newman, Peter Grundt, Robert R. Luedtke
-
Publication number: 20100061928Abstract: The present invention relates to the use of a compound of formula (I): in which R1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R2 and R3 represent, independently of one another, a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.Type: ApplicationFiled: July 27, 2007Publication date: March 11, 2010Applicants: Institut National De La Sante et De La Recherche Medicale (INSERM), Universite D'Auvergne Clermont 1Inventors: Jean-Claude Madelmont, Jean-Michel Chezal, Nicole Moins, Jean-Claude Teulade, Olivier Chavignon
-
Patent number: 7674886Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.Type: GrantFiled: September 4, 2007Date of Patent: March 9, 2010Assignee: Poniard Pharmaceuticals, Inc.Inventor: Sudhakar Kasina
-
Publication number: 20100055036Abstract: The present invention relate to a method for monitoring a response to a therapy on a mammal having a neurodegenerative or neuroinflammatory disorder. According to a preferred embodiment, the method comprising the steps of: a) imaging the mammal using a radio-labeled peripheral benzodiazepine receptor ligand; b) administrating in the mammal at least one anti-amyloid or anti-neuroinflammatory agent; c) imaging the mammal of step b) using a radio-labeled peripheral benzodiazepine receptor ligand; and d) detecting the level of CNS neuroinflammation by the signals from the radio-labeled peripheral benzodiazepine receptor ligand.Type: ApplicationFiled: March 12, 2008Publication date: March 4, 2010Applicant: National Institute of Radiolotgical SciencesInventors: Tetsuya Suhara, Kazutoshi Suzuki, Makoto Higuchi, Ming-Rong Zhang, Jun Maeda, Bin Ji